Table 2.
Demographic and clinical data of the study population
| Characteristics | (n = 43) |
|---|---|
| Age, months | 7 [3–15] |
| Weight, kg | 6.6 [4.7–9.0] |
| Height, cm | 64 [55–74] |
| Male – no. (%) | 23 (54) |
| Comorbidities – no. (%) | 22 (51) |
| Chronic lung disease – no. (%) | 2 (5) |
| Oncological disease – no. (%) | 1 (2) |
| Neurologic disorder – no. (%) | 10 (23) |
| Ex-preterm – no. (%) | 9 (21) |
| Cause of PICU admission – no. (%) | |
| Acute respiratory failure | 33 (77) |
| Neurological disease | 3 (7) |
| Post-operative | 3 (7) |
| Sepsis/septic shock | 4 (9) |
| PEEP, cmH2O | 10 [8–13] |
| FiO2 | 0.6 [0.5–0.8] |
| P/F, mmHg |
100 [78–145] (n = 37) |
| HFOV, no. (%) | 9 (21) |
| Prone position, no. (%) | 24 (56) |
| Vasopressors and inotrpes, no. (%) | 13 (30) |
| PICU LOS, days | 9 [8–14] |
| PICU mortality, no. (%) | 3 (7) |
Demographic and clinical data of the study cohort. Data are expressed as median [interquartile range] or as number (percentage). Reported respiratory variables refer to the worst values of the 48-h study period. PEEP = positive end-expiratory pressure; FiO2 = Fraction of inspired oxygen; P/F = ratio between arterial partial pressure of oxygen and FiO2; HFOV = high frequency oscillatory ventilation; Vasopressors and inotropes = use of vasopressors or inotropes (epinephrine, norepinephrine, dopamine or dobutamine) during the study period; PICU LOS = PICU length of stay